Physician profile
John R Shell
NPI 1366446221
$3,762.45
in general payments reported to CMS, 2019-2025
37 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $268 · 2021: $523 · 2022: $1,093 · 2023: $491 · 2024: $463 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.27 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $481.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $297.36 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $275.39 | 2019-2024 | Mounjaro |
| Sunovion Pharmaceuticals INC. | $196.73 | 2019-2020 | |
| Amgen INC. | $193.17 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $190.84 | 2020-2022 | |
| Abbott Laboratories | $137.60 | 2022-2023 | Freestyle Libre 2 |
| Allergan, INC. | $107.47 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $93.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $90.99 | 2019-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company Ltd. | $89.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.15 | 2022 | |
| Pfizer INC. | $72.91 | 2019-2022 | |
| Axsome Therapeutics, INC. | $64.26 | 2023-2025 | Auvelity, Sunosi |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.